pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Cardiomyopathies in 1 studies
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Chronic administration of a nucleotidase-resistant agonist confers a beneficial effect in the CSQ model of heart failure, apparently via an activation of the cardiac P2X receptor." | 1.34 | P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure. ( Cronin, C; Gongora Nieto, M; Harrison, D; Jacobson, KA; Joshi, BV; Liang, BT; Shen, JB; Sonin, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shen, JB | 1 |
| Cronin, C | 1 |
| Sonin, D | 1 |
| Joshi, BV | 1 |
| Gongora Nieto, M | 1 |
| Harrison, D | 1 |
| Jacobson, KA | 1 |
| Liang, BT | 1 |
1 other study available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Cardiomyopathies
| Article | Year |
|---|---|
P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure.
Topics: Adenine Nucleotides; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Benzenesulfonates; Ca | 2007 |